Intellia Therapeutics Inc (NASDAQ:NTLA)’s share price rose 5.1% during mid-day trading on Tuesday . The company traded as high as $14.39 and last traded at $14.38, approximately 387,800 shares were traded during trading. A decline of 32% from the average daily volume of 572,118 shares. The stock had previously closed at $13.68.

Several equities analysts have commented on the stock. Chardan Capital reissued a “buy” rating and issued a $57.50 target price on shares of Intellia Therapeutics in a report on Tuesday, May 28th. BidaskClub downgraded shares of Intellia Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, August 28th. Robert W. Baird assumed coverage on shares of Intellia Therapeutics in a research report on Monday, July 8th. They set an “outperform” rating and a $23.00 price target on the stock. ValuEngine cut shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, August 26th. Finally, Roth Capital started coverage on shares of Intellia Therapeutics in a research report on Monday, June 10th. They set a “neutral” rating and a $16.00 price objective for the company. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $25.56.

The stock has a market cap of $661.35 million, a price-to-earnings ratio of -7.26 and a beta of 2.72. The company has a quick ratio of 7.99, a current ratio of 7.99 and a debt-to-equity ratio of 0.05. The company has a 50 day simple moving average of $16.31 and a 200 day simple moving average of $16.03.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.05. The company had revenue of $11.10 million for the quarter, compared to the consensus estimate of $7.15 million. Intellia Therapeutics had a negative net margin of 242.65% and a negative return on equity of 33.03%. The firm’s quarterly revenue was up 44.2% compared to the same quarter last year. During the same period last year, the company posted ($0.52) EPS. As a group, analysts predict that Intellia Therapeutics Inc will post -2.29 earnings per share for the current fiscal year.

A number of large investors have recently modified their holdings of the stock. Royal Bank of Canada increased its holdings in shares of Intellia Therapeutics by 277.9% during the second quarter. Royal Bank of Canada now owns 133,723 shares of the company’s stock worth $2,189,000 after buying an additional 98,339 shares in the last quarter. Voloridge Investment Management LLC bought a new stake in Intellia Therapeutics during the 2nd quarter worth $539,000. Nuveen Asset Management LLC bought a new stake in Intellia Therapeutics during the 2nd quarter worth $2,416,000. UBS Asset Management Americas Inc. acquired a new position in Intellia Therapeutics in the 2nd quarter worth about $299,000. Finally, Balyasny Asset Management LLC increased its holdings in Intellia Therapeutics by 25.6% in the 2nd quarter. Balyasny Asset Management LLC now owns 57,321 shares of the company’s stock worth $938,000 after purchasing an additional 11,675 shares in the last quarter. 79.39% of the stock is owned by institutional investors and hedge funds.

Intellia Therapeutics Company Profile (NASDAQ:NTLA)

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.

See Also: Percentage Decliners

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.